Theranexus SA Cash Flow Conversion Efficiency

Latest as of December 2025: -0.305x

Theranexus SA cash flow conversion efficiency. Based on the latest financial reports, Theranexus SA (ALTHX) has a cash flow conversion efficiency ratio of -0.305x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-883.76K ≈ $-1.03 Million USD) by net assets (€2.90 Million ≈ $3.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Theranexus SA (2015–2025)

Cash flow conversion efficiency of Theranexus SA from 2015 to 2025. This chart illustrates how Theranexus SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Theranexus SA (ALTHX) share price today for real-time trading data and today's change.

Theranexus SA Cash Flow Conversion Ratio Explained

Theranexus SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Theranexus SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Theranexus SA ranked by their cash flow conversion efficiency. Also see Theranexus SA (ALTHX) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Strongpoint ASA OL:STRO	0.061x
Neontech Co. Ltd KQ:306620	0.108x
Byuksan Corp KO:007210	0.029x
Cherrybro co.Ltd KQ:066360	0.064x
Toba Pulp Lestari Tbk JK:INRU	-0.187x
Griñó Ecologic S.A MC:GRI	0.050x
WooGene B&G Co. Ltd KQ:018620	0.015x
Asahi Songwon Colors Limited NSE:ASAHISONG	0.204x

Annual Cash Flow Conversion Efficiency for Theranexus SA (2015–2025)

The table below shows the annual cash flow conversion efficiency of Theranexus SA from 2015 to 2025. Review Theranexus SA free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€2.90 Million ≈ $3.39 Million	€-883.76K ≈ $-1.03 Million	-0.305x	-114.98%
2024-12-31	€-1.66 Million ≈ $-1.94 Million	€-3.37 Million ≈ $-3.94 Million	2.033x	+171.04%
2023-12-31	€2.22 Million ≈ $2.60 Million	€-6.36 Million ≈ $-7.43 Million	-2.862x	-205.08%
2022-12-31	€5.73 Million ≈ $6.70 Million	€-5.37 Million ≈ $-6.28 Million	-0.938x	-52.84%
2021-12-31	€10.18 Million ≈ $11.90 Million	€-6.25 Million ≈ $-7.31 Million	-0.614x	-11.20%
2020-12-31	€10.28 Million ≈ $12.02 Million	€-5.68 Million ≈ $-6.64 Million	-0.552x	-8.61%
2019-12-31	€9.98 Million ≈ $11.66 Million	€-5.07 Million ≈ $-5.93 Million	-0.508x	-21.77%
2018-12-31	€13.41 Million ≈ $15.68 Million	€-5.60 Million ≈ $-6.54 Million	-0.417x	-312.77%
2017-12-31	€18.71 Million ≈ $21.87 Million	€-1.89 Million ≈ $-2.21 Million	-0.101x	+99.38%
2016-12-31	€89.85K ≈ $105.05K	€-1.47 Million ≈ $-1.72 Million	-16.406x	-3069.12%
2015-12-31	€1.68 Million ≈ $1.96 Million	€-867.96K ≈ $-1.01 Million	-0.518x	--

About Theranexus SA

PA:ALTHX France Biotechnology

Market Cap

$56.14 Million

€48.02 Million EUR

Market Cap Rank

#21889 Global

#343 in France

Share Price

€3.33

Change (1 day)

+0.45%

52-Week Range

€1.57 - €4.59

All Time High

€22.70